Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

TenNor Enters Research Collaboration with Janssen for Potential New Treatments for Nontuberculous Mycobacteria Diseases

SUZHOU, China, Jan. 18, 2021 /PRNewswire/ -- TenNor Therapeutics (Suzhou) Limited, a clinical-stage biopharmaceutical company dedicated to research and development of differentiated products for the treatment of diseases associated with bacterial infections and dysbioses, announced today that it ...

2021-01-18 21:00 1390

Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy Products

SUZHOU, China, Jan. 15, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted the Medical Products Manuf...

2021-01-15 21:00 2823

ATIF Holdings Limited Announces Its IPO Client Soars 100% in the U.S. Trading Debut

LOS ANGELES, Jan. 13, 2021 /PRNewswire/ -- ATIF Holdings Limited (Nasdaq: ATIF, "ATIF"), a company providing business consulting and media services in Asia and North America, announces the client ofATIF, a China-based pharmaceutical and chemical products manufacturer, Qilian International Holding...

2021-01-13 21:00 9841

China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL

SUZHOU and SHANGHAI, China, Jan. 13, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted approval fo...

2021-01-13 21:00 1538

Korea Fair Trade Commission Assigns Compliance Program Rating of "A" to Yuyu Pharma

SEOUL, South Korea, Jan. 11, 2021 /PRNewswire/ -- Yuyu Pharma (CEO Robert Wonsang Yu, KRX: 000220) received Compliance Program (CP) Rating of "A" from the Korea Fair Trade Commission (FTC). Yuyu Pharma (Yuyu) established its CP team in 2016 with the help of the law firm Kim & Chang. The CP tea...

2021-01-11 22:00 4469

VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China

SHANGHAI, Jan. 9, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients inGreater China, announced today the closing of a$150 million Series B financing. The round...

2021-01-09 11:06 5605

Gracell Biotechnologies Announces Pricing of Initial Public Offering

SUZHOU and SHANGHAI, China, Jan. 8, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical ne...

2021-01-08 14:55 9385

Bioworkshops successfully passed EU QP audit

SUZHOU, China, Jan. 6, 2021 /PRNewswire/ -- In November 2020, Bioworkshops passed a European drug Qualified Person audit (QP audit) for manufacture of clinical drug substance and drug product at their Suzhou site. The ratification of compliance to EU GMP comes within a month of obtaining a Drug M...

2021-01-06 22:00 1597

PharmAbcine to participate in BIO @ JPM and Biotech Showcase Digital during "J.P. Morgan Week 2021"

DAEJEON, South Korea, Jan. 4, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in BIO @ JPM and Biotech Showcase during the J.P. Morgan Wee...

2021-01-04 21:00 1684

ImmVira Announces Series C Financing with Leading Specialist Investors

SHENZHEN, China, Dec. 31, 2020 /PRNewswire/ -- ImmVira Group Company ("the Company"), a biotechnology platform dedicated to the development of oncolytic virus("OV") and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C fina...

2020-12-31 19:29 3710

ImmVira Announces Series C Financing with Leading Specialist Investors

Yuyu Pharma was recognized as "Family-Friendly Company" by the Ministry of Gender Equality and Family

SEOUL, South Korea, Dec. 30, 2020 /PRNewswire/ -- Yuyu Pharma(CEO Robert Wonsang Yu, KRX: 000220) received recognition from the Ministry of Gender Equality and Family for implementing family-friendly policies for their employees. This is the second-time Yuyu has received this certification from ...

2020-12-30 22:00 2717

Arctic Vision obtains the first IND approval for the treatment of UME in China, Suprachoroidal space (SCS) injection potentially brings more benefits to patients

SHANGHAI, Dec. 25, 2020 /PRNewswire/ -- Arctic Vision, a China-based clinical-stage ophthalmology company with a leading portfolio of breakthrough technologies, announced on December 24th the clearance of the Investigational New Drug (IND) for Phase III trial of ARVN001 (triamcinolone acetonide s...

2020-12-25 21:00 3348

Foresee Pharmaceuticals Announces Completion of US$47 Million Financing

TAIPEI, Dec. 24, 2020 /PRNewswire/ -- Foresee pharmaceuticals (TPEx: 6576.TWO) ("Foresee") announces that it has successfully completed an underwritten public offering of 15,000,000 shares of its common stock to the public at a price of NT$88 per share. The aggregate gross proceeds to Foresee from...

2020-12-24 18:00 10500

Senhwa Biosciences Receives US FDA 'Study May Proceed' Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461

TAIPEI and SAN DIEGO, Dec. 23. 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has received a "Study May Proceed" letter fr...

2020-12-24 10:40 2876

Conbercept: New Generation of Product for Treatment of nAMD Completes 36-week Primary Endpoint Visits of Phase III Trial

CHENGDU, China, Dec. 23, 2020 /PRNewswire/ -- Chengdu Kanghong Pharmaceutical Group ("Kanghong") announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, double-masked, parallel-gr...

2020-12-23 22:40 6299

I-Mab Announces Upcoming Participation at January Conferences

SHANGHAI and GAITHERSBURG, Md., Dec. 23, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in Januar...

2020-12-23 21:00 5751

Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19

SEOUL, South Korea, Dec. 22, 2020 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ symbol: 048410) announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for thepotential treatment of patients with severe ...

2020-12-23 10:09 1680

Pierre Fabre Selects AGC Biologics as CDMO to manufacture the orphan drug ER-004

SEATTLE, Dec. 21, 2020 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced its partnership with Laboratoire Pierre Fabre to manufacture ER-004 – an intra-amniotic drug that will pioneer the treatment of a rare and...

2020-12-21 23:00 1596

Longevity Acquisition Corporation Announces 4D pharma Joining Landmark Parkinson's Progression Markers Initiative

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onDecember 18, 2020, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of L...

2020-12-21 21:00 10875

ImmuneMed's hzVSF-v13, COVID-19 clinical trials accelerate development of the treatment

Followed by Russia, Indonesia, and Korea, the second phase of the COVID-19 clinical trial was approved inItaly on Friday, December 18, 2020. CHUNCHEON, South Korea, Dec. 20, 2020 /PRNewswire/ -- The broad spectrum antiviral therapeutic, 'hzVSF-v13(humanized Virus Suppressing Factor)' being devel...

2020-12-21 10:43 1172

1 ... 110 111 112113114 115 116 ... 126